# Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

> **NCT02040480** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2110183 Gelatin Capsule
- **DRUG:** GSK2110183 IR Tablet

## Key facts

- **NCT ID:** NCT02040480
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-05
- **Primary completion:** 2014-04-04
- **Final completion:** 2014-04-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040480, "Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02040480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*